[1] Development and Characterization of the Novel Orally Bioavailable EZH1/2 Dual Inhibitor DS-3201. Honma D, Adachi N, Kanno O, Watanabe J, Hirasawa M, Nosaka E, Shiroishi M, et al. Program: Oral and Poster Abstracts | Session: 802. Chemical Biology and Experimental Therapeutics: Poster I – Saturday, December 9, 2017, 5:30 PM-7:30 PM.
[2] What Are the Key Statistics About Non-Hodgkin Lymphoma? American Cancer Society. Non-Hodgkin?s Lymphoma. 2017. Online. Last accesses December 9, 2017. https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/key-statistics.html
[3] Ferlay J, et al. GLOBOCAN 2012 v1.0. Cancer Incidence and Mortality Worldwide; IARC CancerBase No. 11. 2013.
[4] Chao MP. Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies. Cancer Manag Res. 2013 Aug 23;5:251-69. doi: 10.2147/CMAR.S34273. eCollection 2013.
Home Development and Characterization of the Novel
